CHSYF (China Medical System Holdings) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHSYF China Medical System Holdings Ltd CHSYF
87 GF Score
Price $1.57
GF Value $1.30
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is China Medical System Holdings SpecialCharges?

Special Charges only applies to banks.

CHSYF
87GF Score
China Medical System Holdings Ltd CHSYF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Medical System Holdings (CHSYF) Overvalued in 2026?

Based on GuruFocus' analysis, China Medical System Holdings stock appears to be overvalued. The current stock price of $1.57 is trading 20.8% above its estimated GF Value™ of $1.30. GuruFocus considers China Medical System Holdings to be Modestly Overvalued.

Key valuation signals for CHSYF:

  • SpecialCharges:
  • GF Value™: $1.30 vs. price of $1.57 (20.8% above fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the CHSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Medical System Holdings Business Description

Address 510 King’s Road, Unit 2106, 21st Floor, Island Place Tower, North Point, Hong Kong, HKG
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
87GF Score

Get the complete analysis for CHSYF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price
$1.30
GF Value